Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19
Moderna shares slide as it slashes revenue forecast
Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory syncytial virus (RSV) vaccines.
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop 17% As Investors Eye $30 Support Level
Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication.
justthenews9d
Moderna buried child's death in COVID booster trial in EU report, FDA response called 'misleading'
Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...
pharmaphorum8d
Moderna unveils first clinical data on bivalent COVID variant booster
Moderna has reported preliminary clinical ... "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel.
Vox29d
You’ve never heard of the Covid booster with the fewest side effects
The first time I got a Novavax Covid vaccine, it felt almost subversive. Over the previous few years, every mRNA-based booster I’d gotten — the ones made by Moderna and Pfizer — had felt ...
Is Moderna a Bad-News Buy for 2025?
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
pharmaphorum6d
UK first to approve Moderna's Omicron booster jab
The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna’s Struggles Could Complicate Bird Flu Fight. What It Means for a Potential Vaccine.
Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.
FiercePharma2d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...